Member Info for init2oneit

Can such potential be unlocked at Arcturis.

AI pioneer is laughing all the way back to the bank

https://www.thetimes.co.uk/article/5cf81ff0-a8a8-11ed-9c9e-78cbfe4237a1?shareToken=1d9ce9ad451e72f6b004e762a801f2f6

https://uk.linkedin.com/in/dr-janie-baxter-99240a166

…. and the Arcturis website has had ‘full website coming soon’ since around the middle of November.

Huma have still made no mention of their acquisition from Arcturus. Yet they happy to release this

https://www.prnewswire.co.uk/news-releases/huma-to-provide-best-in-class-digital-clinical-trials-solutions-through-landmark-acquisition-of-alcedis-301715943.html

https://www.phesi.com/

Still suspect some ongoing negotiations for corporate action.

Still a waiting game. Accounts still not published at Companies House for year ending Apr 22. . No info anywhere from the divestment even the purchaser has made No statement and this month the loans notes are due to be settled. Website still displays ‘more soon ‘

What about monies received from the Huma deal. There is nothing published anywhere about this deal other than on the old Sensyne website.

The Website has now been up for 4 weeks. With ‘ more to come soon ‘ statement.

Finally full accounts for year ending Ape 22 when still a public Co not yet published at Companies House.

There is more to come, mark my words.

https://www.evaluate.com/vantage/articles/news/deals-snippets/csl-stops-short-buying-arcturus

Completely as a side issue and linking Arcturus Therapeutics with Arcturis Data is tenuous at best on just the basis of similarity of name. . One wonders why Though CSL held off buying outright. . Arcturus have also been on Merck’s radar

https://www.gurufocus.com/news/1540025/biogen-mirati-and-arcturus-reportedly-on-mercks-radar

There has too been no comment anywhere by Huma about their acquisition from Arcturis, only the statement, on what’s left of the Sensyne website. Financial details of this deal maybe interesting.

By the way the rebranded Co could still have its own identity within a ‘group’ after a buy out. Think jigsaw.

Their main accounts are now 3 weeks late at Companies House too. At Companies House the divisional accounts were issued up to Apr 21. With statements included dated Sep 22 from a board meeting. Due diligence or what.

That may well be the case. But why hold back. There has been no release of rebranding other than the new website. There has to be more as the website suggests. My view is the the rebranding is all part of a much bigger picture. Time will tell.

Good luck to those who held on here. Whatever the route is to get out of this unlisted situation, I believe we could be close to finding out. My gut feeling is still some kind of buy out by a listed Co that could involve a share deal. This would allow all major shareholders to continue to benefit from future activities. Still no real news from the Co directly, so I guess it’s ‘watch this space ‘ for the moment.

That’s a very healthy client base for Phesi. According to info contained in published accounts. The Phesi collaboration is for at least 7 years and the Co put in around 10 M into Phesi

https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence

Phesi have had a little makeover of their website https://www.phesi.com/

Very similar in style to Arcturis Data. All info available points to their collaboration on the synthetic arm project.

I think there could be quite a lot to come once Arcturis fully update their website.

I would not rule out an offer that involves stock in the acquiring Co. It would be a great way to satisfy NHS holders and others. It would allow to be involved in the long term growth potential. I have already pointed out who that could be but it’s just a wild guess. There are many reasons why they would be a good fit and have just secured huge investment.

Backed by AstraZeneca, Huma are obviously adding to their digital health portfolio with the acquisition from Sensyne as per Sensyne Health website.

Some info on Huma

https://www.prnewswire.com/news-releases/huma-and-astrazeneca-partner-to-accelerate-innovation-for-digital-first-patient-care-301507043.html

Hopefully some cash now in the coffers to pay down a little of the loan notes and or cash for working capital.

And here we have it …. Divestment to Huma

https://www.sensynehealth.com/